Assessment of Glecaprevir/Pibrentasvir Treatment

Assessment of Glecaprevir/Pibrentasvir Treatment&rsquo - MDPI

Methods: This study consists of 104 patients with chronic hepatitis C treated with glecaprevir/pibrentasvir and monitored from January to June 2024. Assessments ...

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV ...

In a meta-analysis of real-world data, the mITT SVR12 rate in treatment-naïve patients with compensated cirrhosis who received GLE/PIB treatment ...

Safety analysis of glecaprevir/pibrentasvir in patients with markers of ...

The direct‐acting antiviral (DAA) regimen glecaprevir/pibrentasvir (G/P) is approved for treatment of HCV‐infected patients without cirrhosis and with ...

Real-world effectiveness and safety of glecaprevir/pibrentasvir for ...

The results of this meta-analysis indicate that glecaprevir/pibrentasvir is an effective and well-tolerated pangenotypic treatment option for patients with ...

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with ...

Eight-week glecaprevir/pibrentasvir leads to high rates of sustained virological response at post-treatment week 12 (SVR12) across HCV ...

Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and ...

We performed an integrated analysis of data from trials to evaluate the overall efficacy and safety of 8 weeks of glecaprevir/pibrentasvir in ...

Efficacy and Safety of Glecaprevir/Pibrentasvir for Chronic Hepatitis ...

This meta-analysis of data from 25 clinical trials revealed that 8 or 12 weeks of glecaprevir/pibrentasvir treatment is a safe and effective ...

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 ...

Once-daily treatment with glecaprevir–pibrentasvir for either 8 weeks or 12 weeks achieved high rates of sustained virologic response among ...

Glecaprevir/Pibrentasvir (Mavyret) for the Treatment of Chronic ...

Glecaprevir/pibrentasvir is an effective treatment for any of six genotypes of HCV infection and has few adverse effects.

Glecaprevir-Pibrentasvir Mavyret - Treatment - Hepatitis C Online

Glecaprevir and pibrentasvir are substrates of P-gp and/or BCRP. Glecaprevir is a substrate of OATP1B1/3. Coadministration of MAVYRET with drugs that inhibit ...

Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and ...

Original Article. Pancreas, Biliary Tract, and Liver. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis ...

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients ...

Glecaprevir/pibrentasvir is approved to treat hepatitis C virus genotype 1–6 infection. Patients coinfected with human immunodeficiency virus type 1 achiev.

Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for ...

1). Univariate analysis indicated the SVR12 was significantly lower in patients who previously received SOF treatment (p<0.001), had higher baseline HCV RNA ...

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir ...

The safety profile of glecaprevir/pibrentasvir enhances the confidence of non-liver specialists to treat the majority of HCV-infected patients, ...

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients ...

STUDY OVERVIEW AND TREATMENT ... Part 3 of SURVEYOR‐II (NCT02243293) was a phase 3, partially randomized, open‐label, multicenter study that assessed the efficacy ...

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 ...

The analysis included 693 patients with GT3 infection. SVR12 was achieved by 95% of treatment-naïve patients without cirrhosis receiving 8-week ...

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney... - Hepatology

Conclusion: Once‐daily glecaprevir/pibrentasvir for 12 weeks is a well‐tolerated and efficacious, ribavirin‐free treatment for patients with chronic HCV GT1‐6 ...

Safety and efficacy of glecaprevir/pibrentasvir for the treatment of ...

Glecaprevir/pibrentasvir is a once-daily, all-oral, ribavirin-free, pangenotypic direct-acting antiviral (DAA) combination therapy that has ...

Drug-induced liver injury by glecaprevir/pibrentasvir treatment for ...

Results: The nine studies included in the meta-analysis involved a total of 7,650 participants, and the overall sustained virologic response ...

An integrated analysis of HCV genotype 1–6 patients without cirrhosis

Glecaprevir plus pibrentasvir (G/P) therapy for 8 weeks had an overall cure rate of 98%. •. The efficacy of 12-week G/P therapy (99%) was not significantly ...